Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies

J Natl Cancer Inst. 2015 Jan 31;107(2):dju437. doi: 10.1093/jnci/dju437. Print 2015 Feb.

Authors

Julie A Johnson¹, Issam S Hamadeh², Taimour Y Langaee²

Affiliations

¹ Center for Pharmacogenomics, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL (JAJ, ISH, TYL). johnson@cop.ufl.edu.
² Center for Pharmacogenomics, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL (JAJ, ISH, TYL).

PMID: 25638249
DOI: 10.1093/jnci/dju437

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Adult
Aged
Antineoplastic Agents, Hormonal / pharmacology
Antineoplastic Agents, Hormonal / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / enzymology
Breast Neoplasms / genetics
Breast Neoplasms / prevention & control
Cytochrome P-450 CYP2D6 / genetics*
Drug Administration Schedule
Female
Formaldehyde
Genotype*
Humans
Loss of Heterozygosity*
Middle Aged
Paraffin Embedding
Primary Prevention / methods
Selective Estrogen Receptor Modulators / pharmacology
Selective Estrogen Receptor Modulators / therapeutic use*
Tamoxifen / pharmacology
Tamoxifen / therapeutic use*
Tissue Fixation

Substances

Antineoplastic Agents, Hormonal
Selective Estrogen Receptor Modulators
Tamoxifen
Formaldehyde
Cytochrome P-450 CYP2D6

Grants and funding

U01-GM074492/GM/NIGMS NIH HHS/United States